Project Grant R44CA310518
Award Date 9/17/25
Completion Date 8/31/27
Dollars Obligated $1.4M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Andover, MA 01845, USA
Similar Awards
- The National Cancer Institute awarded a $984,830 Project Grant to EF Therapeutics Corp. under the Cancer Treatment Research federal grant program (CFDA 93.395). The goal of this 2-year project is to validate and translate the use of gene electrotransfer (GET) with EF Therapeutics' novel IntelliPULSE platform technology to enhance non-viral gene delivery for immunotherapy of solid tumors. The project aims to develop and commercialize next-generation technologies that can be used to administer...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research CFDA program (93.394), has awarded a $3,036,844 Project Grant to the University of Southern California (USC) to develop a wireless, wearable thermo-activator device for precise, localized control of chimeric antigen receptor (CAR) T cell therapy in solid tumors. The project aims to overcome limitations of current MRI-guided focused ultrasound approaches by creating a flexible, portable system that can remotely...
- This $1,296,385 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to accelerate the translation and commercialization of a novel, non-invasive wearable rotating magnetic field therapy device (ONCOMAGNETIC DEVICE or OMTX) targeting the treatment of brain cancers. The device generates spinning oscillating magnetic fields that have demonstrated strong, selective anti-cancer effects on patient-derived glioblastoma (GBM) cells and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Promilead, LLC to activate the TFEB protein and enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The key objectives are to: Determine how TFEB expression and activation in TNBC cells can favorably modulate tumor-associated macrophages to suppress tumor growth. Prior research has shown that TFEB has tumor suppressive roles in breast...
- This $399,300 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an innovative cancer immunotherapy approach at Tiba Biotech LLC, a biotechnology company based in Cambridge, Massachusetts. Specifically, the grant funds the creation of a targeted delivery system that combines enhanced self-amplifying RNA (esRNA) technology and spleen-targeting nanoparticle delivery materials. This platform is designed to stimulate a...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- The National Cancer Institute awarded Myolex, Inc. a $263,052 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop their proprietary MSCAN device leveraging Electrical Impedance Myography (EIM) technology. This project aims to apply EIM for the first time to detect and quantify cancer cachexia, a critical condition impacting half of all cancer patients. The MSCAN device provides a cost-effective, convenient alternative to traditional imaging techniques...
- This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Nanocan Therapeutics Corporation in collaboration with Johns Hopkins University, will fund the development and first clinical trial of an innovative Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel technology. The $998,781 award, with a project period from September 2025 to November 2026, aims to extend the use of local radiotherapy from palliative to potential distant...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...